Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLA-B*1301 screening for dapsone hypersensitivity syndrome
NCT02550080Phase 4Unknown
- Sponsor
- Shandong First Medical University Affiliated Dermatology Hospital
- Start
- Jul 2015
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of dapsone in leprosy (HD), acne vulgaris, psoriasis, urticaria, cutaneous vasculitis (CSVV), sponsored by Shandong First Medical University Affiliated Dermatology Hospital. Status: unknown.
02
Drugs
dapsone
03
Conditions
leprosy (HD)acne vulgarispsoriasisurticariacutaneous vasculitis (CSVV)
Beyond the preview
Go deeper on NCT02550080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02550080.